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Commercially available adenosine analogues 
The following compounds were purchased from commercial suppliers and used without further 
purification. 
 
Adenosine 1 was purchased from Sigma-Aldrich 
 
 
Cordycepin S22 was purchased from Sigma-Aldrich 
 
 





Vidarabine S23 was purchased from Sigma-Aldrich 
 
 
L-Adenosine S24 was purchased from Carbosynth Limited 
 
 
3-Deazaadenosine S26 was purchased from Carbosynth Limited 
 
 
Nebularine S27 was purchased from Carbosynth Limited 
 
 
8-Aminoadenosine 3 was purchased from Carbosynth Limited 
 
 





Toyocamycin 9 was purchased from Sigma-Aldrich 
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aAll results are quoted as the geometric mean±SEM of 3 independent experiments unless otherwise 
stated, pKD=-log10(KD(µM)*10



















































































































































































































The off-rates for quinoline 17 and para-chloro 18 were calculated from the dissociation phase (60-70 
s) by fitting the raw data to the first-order rate equation using Excel: 
    
	

   
Quinoline 17: 
  0.45	
		0.48  0.41		  0.98 
/  1.5			1.4  1.7	 
Para-chloro 18: 
  0.36	
		0.41  0.31		  0.88 
/  1.9			1.7  2.2	 
The 95% confidence intervals of the geometric means are quoted in parenthesis. 
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Fo-Fc electron density figures for ligand-bound HSP72 structures 
 
Fo-Fc electron density maps (green) for HSP72-NBD ligand-bound structures contoured at 3s. A) 
Sangivamycin, compound 10. B) Compound 17 HSP72 (blue) is shown in a ribbon representation. 
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Data collection and refinement statistics for HSP72 co-crystal structures with ligands. 
Ligand Compound 10 Compound 17 
PDB ID 5AQZ 5AR0 
Crystals   
  
Space group P212121 P212121 
Lattice constants   
a (Å) 47.94 68.94 
b (Å) 89.50 70.21 
c (Å) 96.92 84.77 
α (°) 90 90 
β (°) 90 90 
γ (°) 90 90 
   
Data collection   
Beamline Diamond I04-1 Diamond I24 
Date of data collection 29-09-2012 08-12-2012 
Wavelength (Å) 0.9200 0.9686 
Resolution range (Å)  48.46-1.65 46.49-1.90 
(highest-resolution shell values)  (1.68-1.65) (1.94-1.90) 
Observations 283187 (10299) 151157 (3296) 
Unique reflections 50487 (2381) 25878 (919) 
Completeness (%) - Inner shell 99.7 99.7 
Average 99.1 89.3 
Outer shell 97.1 51.1 
Multiplicity 5.6 (4.3) 5.8 (3.6) 
Rmerge (%) 9.9 (198) 13.6 (113) 
I/σ(I) 5.3 (0.3) 4.4 (0.6) 
Mean I/σ(I) 7.1 (0.5) 7.7 (1.7) 
CC1/2
a 0.997 (0.334) 0.993 (0.400) 
Average Mosaicity (º) 0.55 0.15 
   
Structure Solution and 
Refinement    
No. of copies in ASU 1 1 
No. of amino acids 390 379 
No. of water molecules 432 203 
No. of chloride ions 0 1 
No. of ethylene glycol molecules 4 0 
No. of glycerol molecules 0 3 
No. of DMSO molecules 0 2 
R-factor (%) 18.6 17.3 
Rfree (%) 22.1 21.0 
   
Ramachandran plot    
Favored (%) 99.0 99.2 
Outliers (%) 0.0 0.0 
RMSD bonds (Å) 0.010 0.010 
RMSD angles (°) 1.01 1.00 
a Half-dataset correlation coefficient, see: Karplus, P. A.; Diederichs, K. Linking Crystallographic 
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Complete Binding Contacts of Nucleoside ligands for HSP70 
Figure S1 All Close Contacts in the Sangivamycin 10/HSP72-NBD Co-Crystal Structure 
 
All distances are in Angstoms. The red spheres represent water molecules 
 
Figure S2 All Close Contacts in the Quinoline 17/HSP72-NBD Co-Crystal Structure 
 
All distances are in Angstoms. The red spheres represent water molecules  
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Figure S3 Overlay of ADP/Pi HSP-72 NBD co-crystal structure (copper) and Sangivamycin 10 
HSP72 NBD co-crystal (white) highlighting all key binding residues 
 
 
Figure S4 Overlay of ADP/Pi HSP-72 NBD co-crystal structure (copper) and 8-Quinoline 17 HSP72 





Figure S5 Overlay of Sangivamycin 10 HSP-72 NBD co-crystal structure (white) and 8-Quinoline 17 
HSP72 NBD co-crystal (grey) highlighting all key binding residues 
 
